In addition, FcγRIIIa polymorphisms influence clinical outcomes in colorectal cancer, squamous cell head and neck cancer, and ERBB2/HER2-positive breast cancer patients treated with anti-epidermal growth factor receptor (EGFR) antibodies such as rituximab, cetuximab, and trastuzumab: Patients with FCGR3A-157V/V genotypes had significantly longer survival (Calemma et al., 2012; Gavin et al., 2017; Magnes et al., 2018). This evidence concerns the gene ERBB2 and colorectal cancer.